Articles tagged with Breast Cancer Cells
Tissue stiffness influences cell growth and changes in function by modulating cell contractility, leading to the activation of key growth signaling pathways and increase in cell tension. This study highlights the importance of mechanical forces in tumor development and could lead to the development of new tumor therapies or targets.
Researchers have discovered that the IGF-1 receptor controls 50% of body size in a non-redundant way, suggesting its potential as a target for cancer treatment. Targeting the IGF-1 receptor may lead to cell death and growth regulation in cancer cells.
Researchers found ER-positive/PR-negative tumors may be more aggressive and respond poorly to tamoxifen, while EDNRB mutations are linked to melanoma risk. Farnesyltransferase inhibitors show promise against aerodigestive tract cancer cells.
Researchers at UT Southwestern Medical Center found a compound called GRN163L that blocks the enzyme telomerase, which keeps cells immortal and implicated in most human cancers. The compound works rapidly and in doses considered reasonable for therapy.
Researchers at The Breakthrough Toby Robins Breast Cancer Research Centre discovered the Scaramanga gene, which regulates early breast development and influences nipple number and position. This breakthrough may help understand normal breast formation and connect it to breast cancer.
Researchers at VCU's Massey Cancer Center have discovered a key enzyme involved in the spread of breast cancer cells. The study, published in the Journal of Biological Chemistry, suggests that sphingosine kinases are potential new targets for cancer therapy.
Researchers at McGill University have identified a genetic pathway responsible for breast cancer cell growth, including the FOXA1 gene. This discovery offers a new target for developing more precise treatments with fewer side effects.
Researchers have discovered that cyclin D1 overexpression disrupts BRCA1's normal role as a cancer inhibitor in breast tumors. Cyclin D1 binds to the same estrogen receptor as BRCA1, negating its tumor suppressor function and promoting cell proliferation.
Scientists discover that cyclin D1, overproduced in half of all breast cancers, can disrupt BRCA1's normal role as a cancer inhibitor. Cyclin D1 interferes with BRCA1 function by occupying the same binding site on estrogen receptor alpha, negating its tumor suppressor role.
A gene called TRPS-1 is over-expressed in 90% of breast cancers, making it a potential target for cancer vaccines. Researchers are exploring its role and developing immunotherapy approaches to treat breast cancer.
Researchers found that non-cancerous cells surrounding young breast cancers undergo epigenetic modifications, altering gene function and signaling to tumor cells. This discovery may lead to early cancer diagnosis or predicting cancer risk through detection of epigenetic alterations.
Researchers show that matrix metalloproteinases (MMPs) promote carcinogenesis by breaking down tissue organization and damaging genomic DNA. Treatment with MMP-3 leads to expression of Rac1b, which stimulates the production of reactive oxygen molecules, causing cancer.
Researchers have found that adeno-associated virus type 2 (AAV2) can selectively kill cancer cells while leaving healthy cells intact. The study suggests that AAV2 recognizes abnormal cancer cells and induces apoptosis, making it a promising candidate for an anti-cancer therapy.
Researchers at Mayo Clinic discovered a therapy that removes immune system blockages without harming the immune system, boosting its natural ability to reject breast cancer. T-regulatory cells play a disease-promoting role in breast cancer, and blocking them boosts natural immunity.
Researchers at Penn State have developed a new ceramide-based therapy that targets and destroys breast cancer cells while sparing healthy tissue. The treatment uses liposomes to deliver ceramide to the tumor, where it disrupts mitochondria and causes cell death.
A new polysaccharide, hyaluronan oligomers, has been discovered to sensitize drug-resistant breast cancer cells to several chemotherapeutic drugs by binding to CD44 receptor. Increasing hyaluronan synthesis in cells also increases resistance to drug treatment.
Researchers found that blocking the Odc gene with the drug DFMO prevents cancer development in laboratory models, including lymphoma. The study suggests that a similar approach might prevent or slow cancer development in other types of cancer.
Researchers at Fox Chase Cancer Center found that reducing BRCC36 expression by 80 percent increases the number of breast cancer cells killed by radiation. This discovery holds promise for future breast cancer treatments, targeting radiation-resistant cancer cells.
Researchers at Fox Chase Cancer Center found that human chorionic gonadotropin (hCG) induces permanent genetic changes in the mammary gland, which are related to its breast cancer prevention effect. The studies also showed that pregnancy and hCG inhibit breast cancer in rats.
Researchers found breast cancers in African women more likely to originate from basal-like cells and often lack estrogen receptors, making them less responsive to standard therapies. This study highlights the need for rethinking screening guidelines and treatment approaches for these patients.
Researchers developed a test to measure CDK activity, which accurately predicts tumor response to Tarceva. A second study found that increased CDK activity correlates with sensitivity to Taxol, providing preclinical evidence for developing a novel device to measure CDK activity in human tissue.
Researchers at Georgetown University Medical Center discovered a chocolate compound that stops cancer cell cycles in lab experiments. The compound, pentamer, deactivates tumor suppressor genes and proteins involved in regulating the cell cycle, preventing cancer cells from dividing.
A new cancer test uses the physical strength of each cell to diagnose and stage cancer, reducing the need for biopsies and potentially saving lives. The 'optical stretcher' can detect cancer in as few as 50 cells, allowing for early diagnosis and treatment.
A new study suggests that mammography is catching breast cancer earlier, but the increasing number of in situ cancers poses a challenge to healthcare professionals. The researchers found a sixfold increase in noncomedo DCIS and a nearly fourfold increase in LCIS among postmenopausal women.
Researchers have found a trio of proteins that protect tumor cells from destruction by radiotherapy, and a deeper understanding of their relationship could lead to more effective treatment. Genetic testing could help doctors identify the most effective treatment method for each patient's unique cancer tissue.
USC researchers found that the BRCA1 gene disrupts interactions between different cell types, leading to ovarian cancer. The gene's indirect action may lead to new treatment options by targeting a biochemical mediator.
Researchers developed new methods for diagnosing cancer based on genomic DNA analysis, which detects changes in chromatin structure and cell interaction with the microenvironment. These findings may lead to the design of new cancer therapeutic agents.
Cancer cells' DNA is tightly compacted, making it resistant to enzyme digestion, unlike healthy tissue. The study's findings suggest new diagnostic and therapeutic tools for distinguishing different types of tumors.
Researchers discovered a compound called STA-21 that blocks a key protein, Stat3, in breast cancer cells. This inhibition leads to the death of cancer cells and may increase effectiveness of chemotherapy while reducing treatment toxicity.
Researchers have crystallized polynucleotide kinase (PNK), a key enzyme involved in DNA repair, opening up possibilities for developing drugs that inhibit cancer's ability to repair itself. The discovery builds on existing work and provides new targets for improving treatment effectiveness and preventing cancer growth.
Researchers at Michigan State University have discovered a gene, oct-4, expressed in normal adult stem cells, which could lead to the development of cancer prevention and diagnosis tools. The study found that adult stem cells with the oct-4 gene are more prone to becoming cancerous than those without it.
Researchers at Mayo Clinic have identified a new mechanism by which cancerous cell growth occurs, revealing that Skp2 degrades FOXO1, a tumor suppressor. This degradation abolishes FOXO1's ability to suppress tumors and can be reversed using chemicals that inhibit protein destruction.
Tufts-NEMC researchers have discovered a key enzyme responsible for cancer cell growth and invasion, which can be blocked by new compounds called pepducins. The finding provides a novel therapeutic approach for treating invasive cancers.
The research found that active Stat5 suppressed invasive tumor cell activities and aggregated breast cancer cells into clusters resembling healthy cells. Loss of Stat5 stimulated invasion, supporting its potential as a biomarker to predict risk and outcome in early-stage breast cancer patients.
Researchers have discovered a rare plant compound, SL0101, that inhibits the RSK protein, which is linked to breast cancer cell growth. The compound, found in Forsteronia refracta, prevents the growth of breast cancer cells without affecting normal cells.
Researchers discover viral DNA sequence in MMTV Env protein that transforms mouse breast cells. The study suggests a potential new mechanism for virus-induced breast cell transformation.
A new study published in PNAS demonstrates a gene therapy technique that targets and destroys cancer cells while leaving normal cells unharmed. The technique exploits specific molecules found in cancer cells, allowing it to selectively kill tumors such as prostate, ovarian, breast, brain, and skin cancers.
A study found that breast cancer patients have lower DNA repair capacity compared to control subjects, increasing their risk of breast cancer. Deficient DNA repair capacity was associated with a threefold higher risk in women with poor DNA repair capacity.
A new study by Brown University researchers has discovered a chemical modification that activates the STAT3 protein, which is important for embryonic growth and development. This continuous activation causes breast and prostate cells to develop and move through the body, leading to cancer. The research team found that acetylation, anot...
Researchers aim to understand the growth and spread of breast cancer by targeting tumor stem cells, which are hypothesized to perpetuate cancer growth. The project may lead to a critical adjunct therapy targeting these cells.
Researchers found that reduced CRBP-I function compromises RAR activity, leading to loss of cell differentiation and tumor progression. The study suggests that somatic CRBP-I loss may contribute to breast cancer development and highlights the need for further research into vitamin A's role in cancer prevention.
Researchers found that celecoxib reduced estrogen receptor expression by an average of 9% after six months of treatment. This finding confirms celecoxib's antiproliferative properties and suggests a new potential therapeutic approach for breast cancer prevention.
Recent studies suggest that two chemical signals, Hedgehog and Wnt, play a key role in the development of certain cancers. These signals are also active in normal stem cells that repair damaged tissue, raising the possibility that some cancers may start from these cells with accumulated mutations.
Researchers at Mount Sinai School of Medicine discovered a new mechanism that contributes to the development of some breast and ovarian cancers, involving the Wnt pathway. Compounds blocking this receptor can make cancer cells more sensitive to agents that induce cell death.
Researchers have discovered a lethal attraction between HER2-positive breast cancer cells and organs, explaining why this form of breast cancer is so invasive. The study found that breast cancer cells overexpressing HER2 proteins also ramp up production of CXCR4, leading to a strong chemical signal that attracts them to specific organs.
Researchers identify LRP6 as a potential missing link in the cancer-causing chain, promoting cell proliferation and tumorigenesis. The study found increased LRP6 gene activity in human tumor samples from patients with breast and colon cancers.
A newly discovered protein, PICT-1, has been found to regulate PTEN stability by regulating phosphorylation. This discovery represents a huge breakthrough in understanding the tumorigenic pathways of breast and prostate cancers.
A pilot study found that ductal lavage detected only half of the cancers in breasts with known cancer. The procedure's effectiveness is limited by poor agreement between cytologic analysis and microscopic results. Mammography and physical examination remain the most effective methods of early detection.
Researchers found ductal lavage detected only half of cancers in breasts with known cancer, possibly due to failure to yield fluid or cells misclassified as benign. The procedure's lack of effectiveness casts doubt on its use as a screening tool for high-risk women.
A new method developed by Princeton scientists can detect small chromosome alterations in cancer cells with high accuracy. The technique allows researchers to identify previously unknown additions and deletions, which may lead to new treatments for breast cancer.
A novel vitamin E compound, alpha-TEA, has been found to effectively reduce primary tumor mass and prevent lung metastases in genetically identical mice. The compound also shows promise in blocking breast cancer cell proliferation and inducing apoptosis.
Researchers at Temple University validated the c-myb gene as a potential cancer drug target by demonstrating its critical role in white blood cell formation. The study found that deleting the gene reduced cell proliferation and the risk of developing cancer, offering hope for future breast cancer treatments.
Researchers have identified a protein tag that is unique to cancer cells and can be targeted by a drug delivery system. The strategy showed effectiveness in laboratory tests and animal models, and the team plans to test it next in human tumors.
Researchers discovered that HER-2 protein receptors can travel into the nucleus and turn on genes associated with different carcinogenesis pathways, including COX-2. This finding may change treatment strategies and open up new avenues of research.
Researchers at Memorial Sloan-Kettering Cancer Center have discovered a new protein that plays a key role in cancer progression. The study found that the loss of PML function disrupts TGF-b signaling, leading to uncontrolled cell growth and tumor development.
Researchers at the University of Illinois have found that sulforaphane, a compound in broccoli and other cruciferous vegetables, can block the growth of late-stage breast cancer cells by disrupting microtubules. This discovery could lead to new strategies for preventing and treating breast cancer.
Researchers developed first mouse embryos without D-type cyclins, which sparked hope for anti-cancer therapy. The triple-knockout mice followed a normal course of cell division until late stages, contradicting previous theory and experiments.
A study using CellSearch technology found that women with high tumor cell levels in their blood had poor treatment outcomes. Women whose circulating tumor cell levels dropped after starting therapy fared much better.
Researchers found that NF-kB is essential for the initial transition stage of epithelial-mesenchymal transition in breast cancer cells. Inhibiting NF-kB after transition prevents cells from becoming invasive.
Researchers at Stanford Medicine have identified leukemia stem cells in chronic myelogenous leukemia, a breakthrough that could lead to new targeted therapies. The discovery reveals that normal adult cells can mutate into cancer stem cells, which are resistant to chemotherapy and require a specific protein called Wnt to self-renew.